B cells and B cell directed therapies in CNS inflammation
(B08)
Subject Area
Clinical Neurology; Neurosurgery and Neuroradiology
Term
from 2012 to 2024
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 213904703
B cells are an important therapeutic target in MS. In this proposal, we aim to investigate the mechanism of action of different B cell directed therapies that are currently in use or being developed. Specifically, we want to (i) understand why blocking of B cell survival factors by atacicept worsened MS, (ii) characterize CD3+CD20+ T cells in the CNS, and (iii) analyze effects of BTK-inhibition on antibody secreting cells. We combine analysis of autoptic MS tissue, CSF of MS patients and human plasma cells, with in vivo analyses in spontaneous B cell dependent EAE, and in an EAE model featuring ectopic lymphoid follicles in the CNS.
DFG Programme
CRC/Transregios
